Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02962050 · ClinicalTrials.gov registry record
Delineating Swallowing Impairment and Decline in ALS
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 109
- Enrollment target
NCT02962050: Completed study, sponsored by University of Florida.
NCT02962050 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02962050 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
The purpose of this study is to 1) evaluate the discriminant ability of simple clinical markers to detect swallowing impairment in individuals with ALS, 2) develop and validate a minimally invasive clinical screening tool for use at multidisciplinary ALS clinics, and 3) determine the natural history of swallowing impairment and decline in ALS.
Primary Outcome
The DIGEST scale will be used by trained, blinded raters to assign ratings of safety to bolus trials. Both efficiency and safety will be assigned a score from 0-4 (more safe/efficient - less safe/efficient) and based on these ratings, will be given a total score ranging from 0-4 that captures their DIGEST rating.
Interventions
- PROCEDURE Videofluoroscopic Swallowing Study (VFSS)
- DEVICE Voluntary Peak Cough Flow Testing
- DEVICE Iowa Oral Performance Instrument
- DRUG Capsaicin Challenge
- DEVICE Pulmonary Function Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2023-02-16 |
What the finished NCT02962050 record still lists
NCT02962050 is an observational study that tracks outcomes without assigning an intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which Videofluoroscopic Swallowing Study (VFSS) is the first listed.
NCT02962050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02962050 about?
NCT02962050 is a clinical study titled "Delineating Swallowing Impairment and Decline in ALS". The purpose of this study is to 1) evaluate the discriminant ability of simple clinical markers to detect swallowing impairment in individuals with ALS, 2) develop and validate a minimally invasive clinical screening tool for use at multidisciplinary ALS clinics, and 3) determine the natural history...
What is the current status of trial NCT02962050?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2017-05-31. Estimated completion is 2023-02-16.
What interventions are being tested in trial NCT02962050?
The interventions under investigation include: Videofluoroscopic Swallowing Study (VFSS) (PROCEDURE), Voluntary Peak Cough Flow Testing (DEVICE), Iowa Oral Performance Instrument (DEVICE), Capsaicin Challenge (DRUG), Pulmonary Function Testing (DEVICE).
Who is sponsoring clinical trial NCT02962050?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI